These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 22421069)

  • 1. Potential role of cortical 5-HT(2A) receptors in the anxiolytic action of cyamemazine in benzodiazepine withdrawal.
    Benyamina A; Naassila M; Bourin M
    Psychiatry Res; 2012 Jul; 198(2):307-12. PubMed ID: 22421069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome.
    Bourin M; Dailly E; Hascöet M
    CNS Drug Rev; 2004; 10(3):219-29. PubMed ID: 15492772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes.
    Benyamina A; Arbus C; Nuss P; Garay RP; Neliat G; Hameg A
    Eur J Pharmacol; 2008 Jan; 578(2-3):142-7. PubMed ID: 17936750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind, comparative study of cyamemazine vs. bromazepam in the benzodiazepine withdrawal syndrome.
    Lemoine P; Kermadi I; Garcia-Acosta S; Garay RP; Dib M
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jan; 30(1):131-7. PubMed ID: 16243418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A positron emission tomography (PET) study of cerebral dopamine D2 and serotonine 5-HT2A receptor occupancy in patients treated with cyamemazine (Tercian).
    Hodé Y; Reimold M; Demazières A; Reischl G; Bayle F; Nuss P; Hameg A; Dib M; Macher JP
    Psychopharmacology (Berl); 2005 Jul; 180(2):377-84. PubMed ID: 15948013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes.
    Hameg A; Bayle F; Nuss P; Dupuis P; Garay RP; Dib M
    Biochem Pharmacol; 2003 Feb; 65(3):435-40. PubMed ID: 12527336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2 and serotonin 5-HT (2A) receptor occupancy as measured by positron emission tomography (PET).
    Hodé Y; Benyamina A; Arbus C; Reimold M
    Psychopharmacology (Berl); 2011 Oct; 217(3):315-21. PubMed ID: 21479533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice.
    Bourin M; Nic Dhonnchadha BA ; Claude Colombel M; Dib M; Hascoët M
    Behav Brain Res; 2001 Sep; 124(1):87-95. PubMed ID: 11423169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-HT2 ligands in the treatment of anxiety and depression.
    Quesseveur G; Nguyen HT; Gardier AM; Guiard BP
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1701-25. PubMed ID: 22917059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity.
    Alvarez-Guerra M; d'Alché-Birée F; Wolf WA; Vargas F; Dib M; Garay RP
    Psychopharmacology (Berl); 2000 Jan; 147(4):412-7. PubMed ID: 10672635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Involvement of some subtypes of 5-HT2-receptors in affective behavior in female rats].
    Fedotova IuO; Ordian NE; Frolova HO; Soboliev VI
    Fiziol Zh (1994); 2012; 58(6):75-80. PubMed ID: 23530416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyamemazine decreases ethanol intake in rats and convulsions during ethanol withdrawal syndrome in mice.
    Naassila M; Legrand E; d'Alche-Birée F; Daoust M
    Psychopharmacology (Berl); 1998 Dec; 140(4):421-8. PubMed ID: 9888617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind study of cyamemazine and diazepam in the alcohol withdrawal syndrome.
    Favre JD; Allain H; Aubin HJ; Frija-Orvoen E; Gillet C; Lejoyeux M; Payen A; Weber M; Garcia-Acosta S; Kermadi I; Dib M
    Hum Psychopharmacol; 2005 Oct; 20(7):511-9. PubMed ID: 16118830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity.
    Ishibashi T; Horisawa T; Tokuda K; Ishiyama T; Ogasa M; Tagashira R; Matsumoto K; Nishikawa H; Ueda Y; Toma S; Oki H; Tanno N; Saji I; Ito A; Ohno Y; Nakamura M
    J Pharmacol Exp Ther; 2010 Jul; 334(1):171-81. PubMed ID: 20404009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.
    Broderick PA; Hope O; Okonji C; Rahni DN; Zhou Y
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):157-71. PubMed ID: 14687870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of serotonin receptors in the action of atypical antipsychotic drugs.
    Meltzer HY; Massey BW
    Curr Opin Pharmacol; 2011 Feb; 11(1):59-67. PubMed ID: 21420906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anxiolytic properties of the antipsychotic alkaloid alstonine.
    Costa-Campos L; Dassoler SC; Rigo AP; Iwu M; Elisabetsky E
    Pharmacol Biochem Behav; 2004 Mar; 77(3):481-9. PubMed ID: 15006458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.
    Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P
    J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
    Meltzer HY; Huang M
    Prog Brain Res; 2008; 172():177-97. PubMed ID: 18772033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of captodiamine in the withdrawal from long-term benzodiazepine treatment.
    Mercier-Guyon C; Chabannes JP; Saviuc P
    Curr Med Res Opin; 2004 Sep; 20(9):1347-55. PubMed ID: 15383182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.